Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amivantamab - Genmab/Janssen Biotech

Drug Profile

Amivantamab - Genmab/Janssen Biotech

Alternative Names: Ami-LC-MD; Amivantamab admixed with rHuPH20; Amivantamab-vmjw; Bispecific EGFR-cMet antibody; CNTO4424; EGFR-MET bispecific antibody; EGFRxcMET bispecific antibody; JNJ 372; JNJ-61186372; JNJ-6372; RYBREVANT

Latest Information Update: 06 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; Janssen Biotech
  • Developer Janssen Biotech; Janssen Research & Development; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Gastric cancer; Liver cancer; Oesophageal cancer
  • Phase I/II Colorectal cancer
  • Phase I Solid tumours

Most Recent Events

  • 01 Mar 2024 Registered for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV)
  • 26 Feb 2024 Janssen Biotech initiates a phase II COCOON trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, First-line therapy, Metastatic disease, Inoperable/Unresectable) in USA, Taiwan and Malaysia (IV, Infusion) (NCT06120140) (EudraCT2023-505863-35-00)
  • 31 Jan 2024 Jannsen announces intention to submit BLA to US FDA and EMA in Non-small cell lung cancer in 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top